Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
© The Author(s). 2016
Received: 7 October 2016
Accepted: 7 October 2016
Published: 12 October 2016
The original article was published in Arthritis Research & Therapy 2016 18:214
Unfortunately, after publication of this article , it was noticed that the name of Jeffrey N. Miner was captured incorrectly during the production process. The middle initial ‘N’ was missing from the list. The corrected author list can be seen above and the original article has been updated to correct this error.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet J-L, Yeh L-T, Terkeltaub R, Quart B. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18:214. doi:https://doi.org/10.1186/s13075-016-1107-x.View ArticlePubMedGoogle Scholar